Disclaimer: The information provided by Stockify is for educational and informational purposes only and does not constitute investment advice. Stockify is not a SEBI-registered broker, investment advisor, or research analyst. Investments in unlisted shares involve risks. Please consult your financial advisor and conduct your own due diligence before making any investment decision.
I am Shweta Sharma, a seasoned content writer with over 12 years of experience, including expertise developed prior to the rise of AI-driven tools. My primary focus has been in the finance domain, where I specialize in creating clear, intent-driven content that delivers real value to users.
LinkedIn
Mohan Meakin Q1 FY27 results show a 44% revenue decline and 9% drop in profit. Explore financial performance and key investor insights.
SEBI extends IPO size revision relief to March 31, 2027. Learn the 50% fresh issue rule, eligibility, filing conditions and investor impact.
IGX IPO gets SEBI nod on 12 October 2026. Check the 1.67 crore-share OFS, IEX stake sale, FY26 financials and expected listing
Goodluck Defence and Aerospace Q1 FY27 results: Rs. 80 crore revenue, 38% EBITDA margin,Rs. 307.2 crore orders and the latest IPO outlook.
NCDEX guar index revival plans include Guardex and Spicedex. FY26 results, SEBI restrictions and what they mean for NCDEX unlisted shares.
OYO parent PRISM gets a Positive Fitch outlook as earnings and leverage improve. See what it means for investors ahead of the proposed IPO
Cremica Foods IPO may raise Rs.600-700 crore in FY28. Check expected valuation, issue structure, financials, growth plans and key details.
NSE has received a SEBI NOC to launch corporate bond index futures. Here is what the product is, how it works and what happens next.
NCDEX pepper futures are live after a 14-year gap. Check contract specs, Kochi delivery rules, and quality norms.
NSE Share Trades on MSEI: Explore listing-day price, turnover and market cap, and see why reported figures may differ
Thyrocare sells 100% of Nueclear Healthcare for Rs. 141.4 Cr, exits radiology to focus on pathology. Know deal structure, financials, and investor impact.
.webp)